These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34481528)

  • 41. Negative serum (1,3) -β-D-glucan has a low power to exclude Pneumocystis jirovecii pneumonia (PJP) in HIV-uninfected patients with positive qPCR.
    Huang Y; Yi J; Song JJ; Du LJ; Li XM; Cheng LL; Yan SX; Li HL; Liu YM; Zhan HT; Dou YL; Li YZ
    Ann Clin Microbiol Antimicrob; 2023 Nov; 22(1):102. PubMed ID: 37986091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pneumocystis jirovecii pneumonia: a case report.
    Gri J; Jain V
    J Med Case Rep; 2024 Feb; 18(1):52. PubMed ID: 38342895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
    Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
    Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder.
    Yetmar ZA; Duffy D; Smith BH; Vikram HR; Brumble L; Limper AH; Beam E
    Clin Transplant; 2023 Sep; 37(9):e15021. PubMed ID: 37195184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spontaneous pneumomediastinum in anti-MDA5-positive dermatomyositis: Prevalence, risk factors, and prognosis.
    Jin Q; Lin S; Chen X; Xu Y; Tian X; He L; Jiang W; Chen F; Shu X; Lu X; Peng Q; Wang G
    Semin Arthritis Rheum; 2024 Apr; 65():152352. PubMed ID: 38185078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
    Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
    Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
    Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
    Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization?
    Chong WH; Saha BK; Chopra A
    Infection; 2021 Dec; 49(6):1079-1090. PubMed ID: 34059997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
    Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
    Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Host factors and characteristics of hospitalized patients with pneumocystis jirovecii pneumonia].
    Chen RX; Sun YX; Liu XN; Shao C; Huang H; Hu K; Xu J; Li J; Yi X; Zhang ZJ; Xu Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Sep; 45(9):881-887. PubMed ID: 36097925
    [No Abstract]   [Full Text] [Related]  

  • 53. Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease-a Case Series.
    Vieujean S; Moens A; Hassid D; Rothfuss K; Savarino EV; Vavricka SR; Reenaers C; Jacobsen BA; Allez M; Ferrante M; Rahier JF
    J Crohns Colitis; 2023 Apr; 17(4):472-479. PubMed ID: 36223253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk Factors of
    Yoon J; Hong SW; Han KD; Lee SW; Shin CM; Park YS; Kim N; Lee DH; Kim JS; Yoon H
    Gut Liver; 2024 May; 18(3):489-497. PubMed ID: 37867439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
    Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis.
    Jin Q; Fu L; Yang H; Chen X; Lin S; Huang Z; Gao B; Tian X; Jiang W; Shu X; Lu X; Wang G; Peng Q
    J Intern Med; 2023 Apr; 293(4):494-507. PubMed ID: 36682032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal infection risk in anti-melanoma differentiation associated gene 5 dermatomyositis.
    Xu YT; Cao ZY; Lin S; Shu XM; Lu X; Wang GC; Peng QL
    Clin Exp Rheumatol; 2024 Feb; 42(2):237-245. PubMed ID: 38153165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective review of Pneumocystis jirovecii pneumonia over two decades.
    Travis J; Hart E; Helm J; Duncan T; Vilar J
    Int J STD AIDS; 2009 Mar; 20(3):200-1. PubMed ID: 19255271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for Pneumocystis jirovecii pneumonia after kidney transplantation: A systematic review and meta-analysis.
    Cheng B; Qi C; Zhang S; Wang X
    Clin Transplant; 2024 May; 38(5):e15320. PubMed ID: 38690617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer.
    Lee EH; Kim EY; Lee SH; Roh YH; Leem AY; Song JH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Chang J; Park MS
    Sci Rep; 2019 Feb; 9(1):2094. PubMed ID: 30765832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.